losartan has been researched along with Angina at Rest in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria." | 5.11 | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fries, R | 1 |
| Böhm, M | 1 |
| de Zeeuw, D | 1 |
| Remuzzi, G | 1 |
| Parving, HH | 1 |
| Keane, WF | 1 |
| Zhang, Z | 1 |
| Shahinfar, S | 1 |
| Snapinn, S | 1 |
| Cooper, ME | 1 |
| Mitch, WE | 1 |
| Brenner, BM | 1 |
| Cotter, G | 1 |
| Metzkor-Cotter, E | 1 |
| Kaluski, E | 1 |
| Blatt, A | 1 |
| Litinsky, I | 1 |
| Baumohl, Y | 1 |
| Moshkovitz, Y | 1 |
| Vered, Z | 1 |
| Zaidenstein, R | 1 |
| Golik, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Angina at Rest
| Article | Year |
|---|---|
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
2 trials available for losartan and Angina at Rest
| Article | Year |
|---|---|
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc | 2004 |
Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris.
Topics: Adult; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ca | 1998 |